Ticker	Volume	Price	Price Delta
DJIA	15,480.50	+92.87	0.60%
S&P 500	1,675.20	+6.04	0.36%
Nasdaq	3,517.12	+15.00	0.43%

Ticker

Volume

Price

Price Delta

DJIA

15,480.50

+92.87

0.60%

S&P 500

1,675.20

+6.04

0.36%

Nasdaq

3,517.12

+15.00

0.43%

Ticker	Volume	Price	Price Delta
STOXX 50	2,824.36	+2.71	0.10%
FTSE 100	6,829.41	+25.54	0.38%
DAX	8,513.06	+40.86	0.48%

Ticker

Volume

Price

Price Delta

STOXX 50

2,824.36

+2.71

0.10%

FTSE 100

6,829.41

+25.54

0.38%

DAX

8,513.06

+40.86

0.48%

Ticker	Volume	Price	Price Delta
Nikkei	15,627.30	+246.24	1.60%
Hang Seng	23,261.10	-105.29	-0.45%
S&P/ASX 200	5,165.37	-14.69	-0.28%

Ticker

Volume

Price

Price Delta

Nikkei

15,627.30

+246.24

1.60%

Hang Seng

23,261.10

-105.29

-0.45%

S&P/ASX 200

5,165.37

-14.69

-0.28%

WATCH LIVE

Ben Bernanke Testifies Before Congress

Bayer, J&J’s Xarelto Prevented Repeat Strokes in Analysis

By Naomi Kresge - 2011-05-25T10:01:19Z

Bayer AG (BAYN) and Johnson & Johnson (JNJ)’s blood-thinner Xarelto was effective in preventing repeat strokes in an analysis of high-risk patients from the Rocket-AF trial, Bayer said today in a study presented at the European Stroke Conference in Hamburg, Germany.

Patients who took Xarelto, known chemically as rivaroxaban, showed a 13 percent lower risk of having another stroke than patients who took the previous standard therapy warfarin, with a similar risk of bleeding as a side effect and lower rates of fatal bleeding, the Leverkusen, Germany-based company said in a statement.

To contact the reporter on this story: Naomi Kresge in New York at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.